Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
April 28, 2020 at 03:49 am EDT
Share
Henan Lingrui Pharmaceutical Co., Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was CNY 2,157.052 million compared to CNY 2,053.113 million a year ago. Operating income was CNY 341.446 million compared to CNY 294.468 million a year ago. Net income was CNY 294.436 million compared to CNY 243.263 million a year ago. Basic earnings per share from continuing operations was CNY 0.512 compared to CNY 0.412 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
HENAN LINGRUI PHARMACEUTICAL CO., LTD. 
